Novartis India Limited
NSE: NOVARTINDMarket Closed • NSE
Day range
52 week range
Novartis India Limited closed at INR1897.60 (-2.19%) on volume 0.66x its 20-day average, trading 26.7% below its 52-week high.
2026-Q1
Q1 FY2026 Financial Results
PAT moved +56.9% QoQ
2023-07-20
DIVIDEND Announced
Annual General Meeting/Dividend - Rs 10 Per Share/Special Dividend - Rs 37.50 Per Share
2022-07-20
DIVIDEND Announced
Dividend - Rs 10 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.39x
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| — | Dividend | ₹10.00 / share | — | 20 Jul 2023 |
| — | Dividend | ₹10.00 / share | — | 20 Jul 2022 |
| — | Dividend | ₹10.00 / share | — | 17 Aug 2021 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods. [1] It imports various medicines to India from different sources across the globe.[2]
IndiaHealthcare
Is Novartis India Limited Shariah compliant?
Novartis India Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (0.07%) complies with AAOIFI threshold (≤ 33%).
What is Novartis India Limited's current valuation relative to peers?
Novartis India Limited trades at a P/E of 47.9x compared to the sector median of 37x, and a Price-to-Book of 5.7x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.39x. Interest coverage is 73x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at steady rates while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.